Effects of the SERM raloxifene on calcium and phosphate metabolism in healthy middle-aged men

Clinical Cases in Mineral and Bone Metabolism

Volumn 6, Issue 2, 2009, Pages 163-168

  Uebelhart, Brigitte ^a   Herrmann, François ^a   Rizzoli, René ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Bone; Calciotropic hormones; Intestinal calcium absorption; Males; Renal handling

Indexed keywords

CALCITRIOL; CALCIUM; CREATININE; PHOSPHATE; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEX HORMONE; SOMATOMEDIN C;

ADULT; AGED; ARTICLE; CALCIUM ABSORPTION; CALCIUM BLOOD LEVEL; CALCIUM METABOLISM; CALCIUM TRANSPORT; CALCIUM URINE LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HUMAN; HUMAN EXPERIMENT; INTESTINE ABSORPTION; KIDNEY TUBULE ABSORPTION; MALE; MIDDLE AGED; NORMAL HUMAN; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; PHOSPHATE TRANSPORT; PHOSPHATE URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT;

EID: 76249124000     PISSN: 17248914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Rizzoli R, Bonjour JP. Physiology of calcium and phosphate homeostases. In: Dynamics of Bone and Cartilage Metabolism, 2nd edn. Academic Press, San Diego. 2006;345-360.
2. Riggs BL, Khosla S, Melton LJ 3rd. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev. 2002;23: 279-302.
3. Khosla S, Melton LJ 3rd, Riggs BL Clinical review 144: Estrogen and the male skeleton. J Clin Endocrinol Metab. 2002;87:1443-1450.
4. Uebelhart B, Herrmann F, Pavo I et al. Raloxifene treatment is associated with increased serum estradioi and decreased bone remodeling in healthy middle-aged men with low sex hormone levels. J Bone Miner Res. 2004;19:1518-1524.
5. Doran PM, Riggs BL, Atkinson EJ et al. Effects of raloxifene, a selective estrogen receptor modulator, on bone turnover markers and serum sex steroid and lipid levels in elderly men. J Bone Miner Res. 2001;16:2118-2125.
6. Smith MR, Fallon MA, Lee H et al. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab. 2004;89:3841-3846.
7. Bonjour JP, Philippe J, Guelpa G et al. Bone and renal components in hypercalcemia of malignancy and responses to a single infusion of clodronate. Bone. 1988;9:123-130.
8. Bijvoet OL, Morgan DB, Fourman P. The assessment of phosphate reabsorption. Clin Chim Acta. 1969;26:15-24.
9. Pak CY, Kaplan R, Bone H et al. A simple test for the diagnosis of absorptive, resorptive and renal hypercalciurias. N Engl J Med. 1975;292:497-500.
10. Perneger TV. What's wrong with Bonferroni adjustments. BMJ. 1998;316:1236-1238.
11. Cohn EM, Van Den Bemd GJ, Van Aken M et al. Evidence for involvement of 17beta-estradiol in intestinal calcium absorption independent of 1,25-dihydroxyvitamin D3 level in the Rat. J Bone Miner Res. 1999;14:57-64.
12. van Abel M, Hoenderop JG, van der Kemp AW et al. Regulation of the epithelial Ca2+ channels in small intestine as studied by quantitative mRNA detection. Am J Physiol Gastrointest Liver Physiol. 2003;285:G78-85.
13. Van Cromphaut SJ, Rummens K, Stockmans I. et al. Intestinal calcium transporter genes are upregulated by estrogens and the reproductive cycle through vitamin D receptor-independent mechanisms. J Bone Miner Res. 2003;18:1725-1736.
14. Adami S, Gatti D, Bertoldo F et al. The effects of menopause and estrogen replacement therapy on the renal handling of calcium. Osteoporos Int. 1992;2:180-185.
15. McKane WR, Khosla S, Burritt MF et al. Mechanism of renal calcium conservation with estrogen replacement therapy in women in early postmenopause - a clinical research center study. J Clin Endocrinol Metab. 1995;80:3458-3464.
16. Dick IM, Devine A, Beilby J et al. Effects of endogenous estrogen on renal calcium and phosphate handling in elderly women. Am J Physiol Endocrinol Metab. 2005;288:E430-435.
17. Heshmati HM, Khosla S, Burritt MF et al. A defect in renal calcium conservation may contribute to the pathogenesis of post-menopausal osteoporosis. J Clin Endocrinol Metab. 1998;83: 1916-1920.
18. Van Abel M, Hoenderop JG, Dardenne O et al. 1,25-dihydroxyvitamin D(3)-independent stimulatory effect of estrogen on the expression of ECaC1 in the kidney. J Am Soc Nephrol. 2002;13: 2102-2109.
19. Dick IM, St John A, Heal S et al. The effect of estrogen deficiency on bone mineral density, renal calcium and phosphorus handling and calcitropic hormones in the rat. Calcif Tissue Int. 1996;59: 174-178.
20. Uemura H, Irahara M, Yoneda N et al. Close correlation between estrogen treatment and renal phosphate reabsorption capacity. J Chin Endocrinol Metab. 2000;85:1215-1219.
21. Boucher A, D'Amour P, Hamel L. et al. Estrogen replacement decreases the set point of parathyroid hormone stimulation by calcium in normal postmenopausal women. J Chin Endrinol Metab. 1989;68:831-836.
22. Garnero P, Tsouderos Y, Marton I et al. Effects of intranasal 17beta-estradiol on bone turnover and serum insulin-like growth factor I in postmenopausal women. J Clin Endocrinol Metab. 1999;84: 2390-2397.
23. Gibney J, Johannsson G, Leung KC. et al. Comparison of the metabolic effects of raloxifene and oral estrogen in post-menopausal and growth hormone-deficient women. J Chin Endocrinol Metab. 2005;90, 3897-3903.
24. Oleksik AM, Duong T, Pliester N et al. Effects of the selective estrogen receptor modulator, raloxifene, on the somatotropic axis and insulin-glucose homeostasis. J Clin Endocrinol Metab. 2001; 86:2763-2768.
25. Poiraudeau S. Roux C, De Ceuninck F et al. Circulating insulin-like growth factor system changes in women with acute estrogen deficiency induced by GnRH agonist. Osteoporos Int. 1997;7:463-470.
26. Sonnet E, Lacut K, Roudaut N et al. Effects of the route of oestrogen administration on IGF-1 and IGFBP-3 in healthy post-menopausal women: results from a randomized placebo-controlled study. Clin Endocrinol (Oxf). 2007;66:626-631.
27. Meinhardt UJ, Ho KK. Modulation of growth hormone action by sex steroids. Clin Endocrinol (Oxf). 2006;65:413-422.
28. Delmas PD, Ensrud KE, Adachi JD et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab. 2002;87:3609-3617.
29. Ettinger B, Black DM, Mitlak BH et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637-645.
30. Caverzasio J, Montessuit C, Bonjour JP. Stimulatory effect of insulin-like growth factor-1 on renal Pi transport and plasma 1,25-dihydroxyvitamin D3. Endocrinology. 1990;127:453-459.
31. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266-281.